On December 17, 2024, Cipla Ltd’s share price traded 1.06% higher, at ₹1,463.85 as of 11:30 AM on the NSE. The stock opened at ₹1,470.90, lower than the previous close of ₹1,448.45. Over the last 5 days, Cipla Ltd’s share price has decreased by 1.4%.
Cipla’s current PE ratio stands at 26.99, while its PB ratio is 4.06, indicating the company’s valuation relative to earnings and book value, according to BSE data.
Investors are optimistic about Cipla’s prospects, anticipating that the pharmaceutical giant will benefit from upcoming US launches. According to news reports, the market anticipates a domestic recovery and robust growth in South Asia for Cipla.
In the September quarter, the pharmaceutical giant reported a 15% year-on-year (YoY) increase in net profit, reaching ₹1,303 crore. The company’s revenue from operations stood at ₹7,051 crore, marking a 5% YoY growth.
EBITDA for the quarter grew by 8.7%, amounting to ₹1,885.5 crore compared to ₹1,733.8 crore in the previous year.
The company’s India business saw a 5% YoY growth, while Cipla’s North American sales reached $237 million, reflecting a 4% YoY increase during the July-September period.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.
We're Live on WhatsApp! Join our channel for market insights & updates